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Objectives: One in four persons living with HIV is coinfected with hepatitis C virus 
(HCV). Biological and behavioral mechanisms may increase HIV viral load among 
coinfected persons. Therefore, we estimated the longitudinal effect of chronic HCV on 
HIV suppression after ART initiation among women with HIV (WWH).
Design: HIV RNA was measured every 6 months among 441 WWH in the Women’s 
Interagency HIV Study who initiated ART from 2000 to 2015.
Methods: Log-binomial regression models were used to compare the proportion of 
study visits with detectable HIV RNA between women with and without chronic HCV. 
Robust sandwich variance estimators accounted for within-person correlation induced 
by repeated HIV RNA measurements during follow-up. We controlled for confounding 
and selection bias (because of loss to follow-up and death) using inverse probability-of-
exposure-and-censoring weights.
Results: One hundred and fourteen women (25%) had chronic HCV before ART 
initiation. Overall, the proportion of visits with detectable HIV RNA was similar among 
women with and without chronic HCV [relative risk (RR) 1.19 (95% CI 0.72, 1.95)]. Six 
months after ART initiation, the proportion of visits with detectable HIV RNA among 
women with chronic HCV was 1.88 (95% CI 1.41–2.51) times that among women 
without HCV, at 2 years, the ratio was 1.60 (95% CI 1.17–2.19), and by 6 years there 
was no difference (1.03; 95% CI 0.60–1.79).
Conclusion: Chronic HCV may negatively impact early HIV viral response to ART. 
These findings reaffirm the need to test persons with HIV for HCV infection, and 
increase engagement in HIV care and access to HCV treatment among persons with 
HIV/HCV coinfection. 
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Introduction
One in four persons living with HIV in the United States
is coinfected with hepatitis C virus (HCV) [1].
Quantifying the effect of HCV on HIV suppression is
crucial. HIV suppression improves clinical outcomes and
reduces HIV transmission [2,3]. Yet, biological and
behavioral mechanisms may increase HIV viral load
among people with HIV/HCV-coinfection. Common
HIV coinfections, such as tuberculosis and herpes simplex
virus, type 2, increase HIV viral replication [4–6].
Ongoing alcohol and drug use and decreased antiretro-
viral therapy (ART) adherence among coinfected persons
may also result in increased HIV viral load [7,8].
Published studies suggest that persons with HIV/HCV
coinfection do not experience increased time to HIV
suppression after ART initiation [9–17] but HCV may be
associated with earlier failure of HIV viral control [18].
However, there are several limitations in studies
quantifying the effect of HCV on HIV suppression after
ART is begun. Many studies that found no association
between HCV and HIV suppression did not distinguish
between persons with chronic HCV (i.e. seropositive
with detectable HCV RNA) and those who cleared
infection (i.e. seropositive but RNA-negative) [9–14,18];
misclassification of HCV status could result in biased
associations. Also, some studies did not account for
potential confounding of the relationship between HCV
and HIV suppression by alcohol or drug use [11,17].
Evidence regarding the effect of HCV on HIV
suppression after ART initiation is especially lacking
among women. Women respond differently to ART than
men [19–23], often exhibiting more favorable immune
responses [21–23] but experiencing greater drug toxicity
[20] and more frequent treatment discontinuation [19].
To date, there is only one published study assessing the
association between HCV and HIV suppression after
ART initiation among women [24]. That study did not
find an association between HCV status and HIV
suppression, but did not distinguish between women
with chronic HCV and women who cleared infection,
and follow-up was limited to 1 year [24]. The effect of
HCV on HIV viral response to ART among women
warrants further investigation.
The objective of this study was to estimate the
longitudinal effect of chronic HCV on HIV suppression
after ART initiation among women for up to 15 years.
We hypothesized that women with chronic HCV would
be more likely to have detectable plasma HIV RNA than
women without HCV during the follow-up period.
Methods
Study population
We used data collected by the Women’s Interagency HIV
Study (WIHS) for this analysis. A full description of the
WIHS cohort is provided elsewhere [25,26]. Briefly, the
WIHS is a prospective cohort of women living with and
at risk for HIV, with follow-up at 6-month intervals. At
each visit, interviewer-administered questionnaires cap-
ture extensive medical, psychosocial, and drug-use
information. ART use is defined as three or more
antiviral medications approved by contemporaneous
Department of Health and Human Services (DHHS)
guidelines [27]. Between 1994 and 2014, 4982 women
enrolled in the WIHS across 10 study sites; 3677 (74%)
were living with HIV at enrollment and 24 (0.5%)
acquired HIV during follow-up.
Women with HIV who initiated ART on or after 1
January 2000, and after they were enrolled in the WIHS,
were eligible for the present analyses. Women who
initiated ART prior to 2000 were excluded to allow
assessment of HIV suppression with relatively modern
ART regimens. Of the 640 eligible women, we excluded
100 (16%) who did not have HIV RNA measured prior
to ART initiation, 29 (4%) without at least one HIV
RNA measurement after initiating ART, and 23 (4%)
missing HCV infection status. We also excluded 52 HCV-
uninfected women less than 30 years of age at ART
initiation. There were no women with chronic HCV
who were less than 30 years of age at ART initiation and
we did not want to bias our findings by extrapolating to
women who did not exist in our data [28]. Therefore, the
final study sample included 441 women. Demographic
and clinical characteristics were similar between women
included and excluded from our study, including the
proportions with chronic HCV. However, excluded
women were less likely to be black or have liver fibrosis,
and more likely to have initiated ART between 2000
and 2005.
Chronic HCV was defined as the presence of HCV
antibody and HCV RNA prior to ART initiation. HCV-
seropositive women with undetectable HCV RNA were
classified as HCV-uninfected. In the WIHS, women are
screened for HCV with enzyme immunoassays at one of
the first three study visits after enrollment. Chronic
infection is confirmed with HCV RNA among HCV-
seropositive women. The average length of time between
HCV testing and ART initiation was 6 years among
participants and we were concerned that chronic HCV
may be misclassified because of spontaneous HCV
clearance, antiviral treatment, or incident HCV infections
during this time. Therefore, we supplemented HCV results
with follow-up HCV test results (available for over 80% of
women) and HCV treatment initiation. Eleven women
who were HCV-uninfected at enrollment had evidence of
HCV antibodies and RNA prior to ART initiation and
were classified as HCV-infected. Two women classified as
HCV-infected at enrollment were reclassified as HCV-
uninfected because of subsequent negative RNA tests.
Lastly, four women reported HCV treatment prior to ART
initiation. Three of the four women had HCV RNA
testing performed after ART initiation and were still HCV-
infected;we did not change their status. The fourth woman
had undetectable HCV RNA before ART initiation and
was reclassified as HCV-uninfected.
Our outcome of interest was detectable HIV RNA at
each study visit after ART initiation. We defined
detectable HIV RNA as>80 copies/ml to accommodate
assays used during the study period, which had lower
limits of detection ranging from 20 to 80 copies/ml.
Covariate assessment
Baseline covariates, measured at the last study visit prior
to ART initiation, included age, race, year of ART
initiation, history of injection drug use, CD4þ cell count,
HIV RNA, and liver fibrosis. Age was included as a
continuous variable using restricted quadratic splines with
three knots placed at the 5th, 50th, and 95th percentiles
[29]. Race was dichotomized as black or non-black and
history of injection drug use was included as yes/no.
Because our sample size was less than 500, we categorized
several continuous variables: year of ART initiation,
baseline CD4þ cell count, and baseline HIV RNA. Year
of ART initiation was considered a proxy measure for
ART regimen and categorized as 2000–2005, 2006–
2010, and 2011–2015. Baseline CD4þ cell counts were
grouped as less than 200, 200–499, at least 500 cells/ml,
and HIV RNA was categorized as 4000 or less, 4001–
10 000, and more than 10 000 copies/ml. Liver fibrosis
was assessed by the FIB-4 index; scores were dichoto-
mized as more than 1.45 and 1.45 or less to differentiate
women with and without significant fibrosis [30–32].
We considered two time-varying covariates as predictors of
loss to follow-up or death: alcohol and drug use. We
categorized alcohol use as 0, 1–7, and more than 7 drinks
per week since prior study visit. Women were categorized as
current drug users if they reported using any illicit or
recreational drugs since their last study visit. Time-varying
covariateswere missing for 4%of follow-upvisits; thesewere
replaced with values carried forward from the previous visit.
Statistical methods
We used a log-binomial regression model to estimate the
proportion of study visits with detectable HIV RNA
during follow-up, and compared women with and
without chronic HCV. Robust sandwich variance
estimators were used to account for within-person
correlation induced by repeated HIV RNA measure-
ments over the follow-up period. We also planned a
priori to include a product term between HCV status and
time since ART initiation in a second log-binomial
model. Therefore, we could assess whether the relation-
ship between chronic HCVand detectable HIV RNAwas
a function of duration of ART.
Women were followed from the first study visit after ART
use until the last visit prior to 30 September 2015, the last
possible date on which data were available. Women were
right-censored at the earliest occurrence of loss to follow-
up, death, or last visit prior to 30 September 2015. Loss to
follow-up was defined as two consecutively missed study
visits. We also censored women with chronic HCV who
initiated HCV treatment and HCV-uninfected women
who had evidence of HCV antibody and HCV RNA
during follow-up.
To control for confounding, we used time-fixed inverse
probability-of-exposure weights [33,34]. These weights
are fully described in the Supplemental Digital Content;
http://links.lww.com/QAD/B221. Logistic regression
was used to estimate the weights and included age, race,
year of ART initiation, FIB-4, baseline HIV RNA,
baseline CD4þ cell count, and history of injection
drug use.
We created time-varying inverse probability-of-censor-
ing weights to account for right-censoring because of
death or loss to follow-up [35,36] (see Supplemental
Digital Content; http://links.lww.com/QAD/B221).
Pooled logistic regression models were used to estimate
the censoring weights. The models included time, HCV
status, race, age, and time-varying alcohol and drug use.
Time was measured as the number of semiannual study
visits since ART initiation and included in the models
using restricted quadratic splines with knots at the 5th,
50th, and 95th percentiles [29].
Robust variance estimates tend to overestimate the
variability of inverse probability-weighted estimators. We
calculated 95% confidence intervals (CIs) for the
weighted ratio measures using a nonparametric bootstrap
with 200 resamples with replacement.
Sensitivity analyses
We conducted several sensitivity analyses to assess the
robustness of our findings and reduce possible bias in our
estimated effects of chronic HCV on HIV RNA after
ART initiation. In the first, we excluded women who
reported single or dual antiretroviral use prior to ART
initiation. For the second, we only included women who
self-reported more than 95% adherence to ART during
the first 6 months after initiation. This analysis allowed us
to determine if the estimated effect of chronic HCV on
HIV RNA could be explained by poorer ARTadherence
among women with chronic HCV. In the third sensitivity
analysis, we reclassified women who were HCV-
seropositive with undetectable HCV RNA to HCV-
infected, as these women may share some of the same
behaviors that lead to poorer control of HIV.
All data analyses were conducted with SAS version 9.4
(SAS Institute Inc., Cary, North Carolina, USA). The
analysis was approved by the University of North Carolina
at Chapel Hill Institutional Review Board.
Results
Of 441 women, 114 (26%) had chronic HCV before
ART initiation (Table 1). The median age was 47 years
[interquartile range (IQR) 42–51] among women with
chronic HCVand 41 years (IQR 36–47) among women
without HCV. Two-thirds (67%) of all women were black
and approximately one-third (34%) had less than a high
school education. Three-quarters of women had previ-
ously used illicit drugs (75%) and the majority of women
with chronic HCV (87%) had previously injected drugs.
Nine percentage of women with chronic HCV were
actively injecting drugs at baseline and 1% of women
without HCV were.
Overall, half (55%) of women initiated ART from 2000 to
2005 and 22% initiated ART from 2006 to 2010. A greater
proportion of women with chronic HCV initiated ART
from2000 to2005 (70versus 49%amongHCV-uninfected).
At baseline, the median CD4þ cell count was 303 cells/ml
(IQR 188–440) and median HIV RNA was 4.20
log10 copies/ml (IQR 3.27–4.79). These baseline measures
did not differ between women with and without chronic
HCV. HCV genotypes were available for 18 women with
chronic HCV; 9 of these women (50%) were genotype 1a.
The median follow-up was 11 study visits or 5.6 years. Two
hundred and twenty-nine (52%) women completed follow-
Table 1. Baseline characteristics of 441 HIV-infected women initiating antiretroviral therapy by hepatitis C virus status, Women’s Interagency
HIV Study, January 2000–September 2015.
HCVþ (n¼114) HCV (n¼327) Total (n¼441)
Median or n IQRa or % Median or n IQRa or % Median or n IQRa or %
Age at ART initiation (years) 47 42, 51 41 36, 47 43 37, 49
Race/ethnicity
White, non-Hispanic 18 16% 36 11% 54 12%
Black, non-Hispanic 77 68% 217 66% 294 67%
Othera 19 17% 74 23% 93 21%
Educationb
Less than high school 48 42% 103 32% 151 34%
Graduated high school 29 25% 109 33% 138 31%
Some college 37 32% 114 35% 151 34%
Annual household income <$12,000 85 77% 163 51% 248 56%
Alcohol usec
0 drinks per week 60 53% 150 46% 210 48%
One to seven drinks per week 32 28% 135 41% 167 38%
More than seven drinks per week 22 19% 42 13% 64 15%
Ever used noninjection drugs 109 96% 221 68% 330 75%
Ever injected drugs 99 87% 35 11% 134 30%
Chronic active HBVd 1 <1% 8 2% 9 2%
Year of ART initiatione
2000–2005 80 70% 161 49% 241 55%
2006–2010 28 25% 70 21% 98 22%
2011–2015 6 5% 96 30% 102 23%
Single or dual antiretroviral usef 57 50% 92 28% 149 34%
CD4þ cell count at baseline 287.5 172, 392 313 194, 454 303 188, 440
HIV viral load at baselineg 4.16 3.11, 4.84 4.23 3.34, 4.77 4.20 3.27 4.79
FIB-4 greater than1.45 91 80% 70 21% 161 37%
ART, anti-retroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, inter-quartile range.
a Other race/ethnicity includes Hispanic, Native American/Alaskan Native, Asian/Pacific Islander, and races/ethnicities categorized as other.
b Education categories do not add to the total because of missing information.
c Self-reported alcohol use within the last 6 months.
d Chronic, active hepatitis B infection is defined as positive hepatitis B core antibody and positive hepatitis B surface antigen, and measured 
during
one of the first three study visits after enrollment.
e ART is defined as use of three or more antiretroviral medications approved by contemporaneous DHHS guidelines.
f Self-reported use of single or dual antiretroviral prior to ART initiation.
g HIV viral load is reported in log10 copies/ml.
up alive, 86 (20%) died during follow-up, and 110 (25%)
were lost to follow-up. Thirteen women with chronic HCV
were censored because of HCV treatment initiation and
three HCV-uninfected women were censored because of
evidence of HCV acquisition during follow-up.
Table 2 depicts the crude and weighted risk ratios for
detectable HIV RNA comparing women with and
without chronic HCV. There were 5523 total study visits
and HIV RNA was detected at 2064 visits (37%). The
percentage of study visits with detectable HIV RNA was
higher among women with chronic HCV (47 versus
34%). After weighting, the proportion of study visits with
detectable HIV RNA among women with chronic HCV
was 1.19 (95% CI 0.72–1.95) times that of HCV-
uninfected women.
The results of the log-binomial model with a product
term between HCV status and time since ART initiation
are depicted in Fig. 1. Approximately 6 months after ART
initiation, the proportion of visits with detectable HIV
RNA among women with chronic HCV was 1.88 (95%
CI 1.41–2.51) times that among women without HCV,
at 2 years the ratio was 1.60 (95% CI 1.17–2.18), and by 6
years, there was essentially no difference (1.03; 95% CI
0.60–1.79). The P value for a test of linear trend was 0.02,
which indicates the observed trend of risk ratios by time
was unlikely because of chance.
Table 2. Estimated associations between hepatitis C virus infection and detectable HIV viral load among 441 women enrolled in the Women’s
Interagency HIV Study, January 2000–September 2015.
HCVþ (n¼114) HCV (n¼327) Overall (n¼441)
Total study visits 1509 4014 5523
Visits with detectable HIV viral load 708 1356 2064
Proportion of visits with detectable HIV
viral load (95% CI)
0.47 (0.44, 0.49) 0.34 (0.32, 0.35) 0.37 (0.36, 0.38)
Crude risk ratio (95% CI) 1.39 (1.15, 1.68) 1 –
Weighted risk ratio (95% CI)a,b 1.19 (0.72, 1.95) 1 –
CI, confidence interval; HCV, hepatitis C virus
aWeights account for the following set of time-fixed and time-varying covariates: age at ART initiation, race, history of injection drug use, year of
ART initiation, CD4þ cell count at ART initiation, HIV viral load at ART initiation, FIB-4 at ART initiation, current alcohol use, current drug use, and
time.
b95% CI was estimated with a nonparametric bootstrap using 200 samples with replacement.
Fig. 1. Estimated association between chronic hepatitis C virus infection and detectable HIV RNA at each 0.5-year interval
following antiretroviral therapy initiation among 441 HIV-infected women enrolled in the Women’s Interagency HIV Study,
January 2000–September 2015. The open circles represent the risk ratio point estimates. The solid black line represents the linear
trend for the risk ratio point estimates and the dotted lines represent the 95% CI for the trend line. This CI was estimated with a
nonparametric bootstrap using 200 samples with replacement. The line at 1 represents the null effect for a ratio measure. CI,
confidence interval.
There were 149 women (34%) who reported single or
dual antiretroviral use prior to initiation of an effective
ART regimen. After excluding these women, the
association between chronic HCV and HIV RNA after
ART initiation was similar to the main analysis. The
proportion of visits with detectable HIV RNA among
women with chronic HCV was 1.46 times that among
HCV-uninfected women (95% CI 0.74, –2.93). A similar
trend in ratio measures over time was also observed
(P¼ 0.04).
We also observed similar results when we limited our
sample to only those women who reported taking their
ART medications as prescribed during the first 6 months
of ART (n¼ 359). The proportion of visits with
detectable HIV RNA among women with chronic
HCV was 1.05 (95% CI 0.62–1.78) times that among
HCV-uninfected women. There was a similar trend in
risk ratios over time as well (P¼ 0.05); at 6 months the
ratio was 1.68 (95% CI 1.14–2.44), at 3 years the ratio was
1.43 (95% CI 0.98–2.07), and by 6 years, there was no
difference (0.95; 95% CI 0.53–1.69).
Lastly, we observed similar findings when we reclassified
33 women who were HCV antibody-positive with
undetectable HCV RNA as HCV-infected. The propor-
tion of visits with detectable HIV RNA among HIV/
HCV-coinfected women was 1.29 times that among
HIV-monoinfected women (95% CI 0.84–1.96). A
similar trend in ratio measures over time was also observed
(P¼ 0.07).
Discussion
In this longitudinal study of women with HIV initiating
ART, the proportion of study visits with detectable HIV
RNA was similar among women with and without
chronic HCV. However, women with chronic HCV
were more likely to have detectable HIV RNA up to 2
years after ART initiation than women without HCV.
Behavioral and biological mechanisms may explain the
increased risk for detectable HIV RNA among women
with chronic HCV during the first few years after ART
initiation. Women with HCV may have poorer ART
adherence and use alcohol and drugs more frequently
[7,8]. When we repeated our analysis among women
reporting more than 95% adherence during the first 6
months after ART initiation, results were similar to the
main analysis. We controlled for potential confounding of
the relationship between chronic HCVand HIV RNA by
history of injection drug use, and included time-varying
drug and alcohol use in the models used to estimate
inverse probability-of-censoring weights. Thus, the
observed association between chronic HCV and detect-
able HIV RNA is not fully explained by behavioral
differences between women with and without chronic
HCV. Persons living with HIV/HCV coinfection
experience greater immune system dysregulation
[37,38] and HCV has also been shown to replicate in
extrahepatic lymphoid cells [39–41]. Therefore, biologi-
cal interaction between HIV and HCV is possible, and
could decrease ART effectiveness during the first few
years after uptake.
Most of the previous studies assessing the effect of HCV
on HIV treatment outcomes did not find that HCV
negatively impacts HIV suppression [9–17]. Yet, a recent
study by Hua et al. [18] found that HCV was associated
with earlier failure of HIV control, which was defined as
two consecutive detectable HIV RNA measurements 16
or more weeks after ART initiation. In that study,
significantly more HIV/HCV-coinfected patients expe-
rienced viral failure by 48 weeks after ART initiation
[18]. These results also provide evidence that HCV may
negatively impact early HIV viral response to ART.
There are several key differences between the present
study and previous research assessing the effect of HCVon
HIV suppression after ART. Previous studies compared
time to HIV suppression after ART initiation among
persons with and without HCV [9–17]. WIHS data are
interval censored at 6-month time periods, and the
median time to first suppressed viral load in our analytic
sample was approximately 6 months. Therefore, we could
not replicate these analyses with our data. However, other
studies have not assessed the association between HCV
and HIV RNA using repeated measures of HIV RNA
during follow-up, and our study provides a unique view
of the longitudinal effect of chronic HCVon HIV RNA.
We defined HCV infection with confirmation of
detectable HCV RNA. Approximately 15–25% of
persons spontaneously clear their HCV infection (i.e.
HCV RNA becomes undetectable), but remain HCV
antibody-positive [42]. Previous studies often defined
HCV by HCV antibody status only [9–14,18] and were
not estimating the effect of chronic HCV infection on
HIV RNA.
An additional distinction between previous research and
the present study is that our analysis included only
women. Women experience more frequent ART
regimen discontinuation [19] and drug toxicity [20]
than men. Despite this, only one previous study assessed
the effect of HCV on HIV viral response after ART
initiation among women. In unadjusted analyses, Marcus
et al. [24] found that the cumulative incidence of HIV
suppression 1 year after ART initiation was lower among
HIV/HCV-coinfected women than among HIV-mono-
infected women. After adjustment for confounding,
there was no difference in HIV viral response by HCV
status [24] but follow-up was limited to 1 year after ART
initiation [22].
Our study has several limitations. We used observational
data and the possibility of uncontrolled confounding
remains. HCV may also potentiate hepatoxicity after
ART initiation [43,44], which could lead to more
frequent regimen changes and interruptions in therapy
among HIV/HCV-coinfected persons [45,46]. Although
we controlled for clinical characteristics at ART initiation
and year of ART initiation (as a proxy measure for ART
regimen), we did not assess the frequency of ART
regimen changes because of toxicity in our cohort. Drug
toxicities and regimen changes could contribute to the
increased risk for detectable HIV RNA among women
with chronic HCV in our cohort.
Approximately 25% of our sample were lost to follow-up
and 20% died. Our estimated measures of effect would be
biased if there is differential loss to follow-up or death
among women with chronic HCV or among women
with detectable HIV RNA [47,48]. To reduce selection
bias, we created inverse probability-of-censoring weights.
If the models used to construct the censoring weights are
correctly specified and the observed variables fully explain
selection that is associated with the exposure and
outcome, those who were censored would be exchange-
able with those who remained under study in our
weighted sample, and bias would be averted [49].
Nevertheless, the extent to which we achieved
exchangeability is not testable in observational data.
There was also an average of 6 years between baseline
HCV testing and ART initiation. This could result in
poorer clinical outcomes among women with
chronic HCV because of worsening liver function
[37,38,50–53] and misclassification of HCV status. We
included the FIB-4 index in our exposure weights to
control for confounding by declining liver function
among women with chronic HCV. We also minimized
HCV misclassification by supplementing HCV tests at
enrollment with follow-up results and self-reported
HCV treatment initiation. Over 80% of women in our
analytic sample had at least one follow-up result
available. Only 1% of women who were HCV-infected
at enrollment cleared their infection prior to ART
initiation and were reclassified to HCV-uninfected, and
2% of women who were HCV-uninfected at enrollment
were reclassified to HCV-coinfected. We were not able
to account for women classified as HCV-infected at
ART initiation who cleared HCV infection during
follow-up.
The observed associations between chronic HCV and
HIV RNA may not generalize to all women with HIVon
ART in the United States. Our target population was
women who initiated ART after they enrolled in the
WIHS and after year 2000. We used these criteria in
order to observe HIV RNA results at regular intervals,
provide minimal missing information on confounders,
and to assess the effect of chronic HCVon viral response
to relatively modern ART regimens. These criteria
resulted in fewer than 500 women who were eligible
for our study. Although women in the WIHS are
representative of the HIV epidemic among women in
the United States with respect to demographic char-
acteristics [26], we cannot guarantee that the distribution
of effect measure modifiers, like ART adherence,
are similar. Therefore, the ability to generalize our
findings to all women with HIV in the United States is
limited [54].
Conclusion
The results of this study provide a unique view of the
longitudinal effects of chronic HCV on HIV viral
response to ARTamong women. Overall, the proportion
of visits with detectable HIV RNA was similar between
women with and without chronic HCV. However,
women with chronic HCV were more likely to have
detectable HIV RNA up to 2 years after ART initiation
than women without HCV. This finding suggests that
chronic HCV may negatively impact early HIV viral
response to ART. Despite new treatment options for
persons with HCV, 45–85% of those with HCV are
unaware of their infection [55–58] and considerable
barriers to HCV treatment remain [59,60]. Thus, our
findings reaffirm the need to test persons with HIV for
HCV infection, and increase engagement in HIV care
and access to HCV treatment among persons with HIV/
HCV coinfection.
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